VANDA PHARMACEUTICALS INC
NASDAQ: VNDA (Vanda Pharmaceuticals Inc.)
Kemas kini terakhir: 1 jam lalu5.04
-0.21 (-4.00%)
| Penutupan Terdahulu | 5.25 |
| Jumlah Dagangan | 956,724 |
| Harga / Pendapatan (P/E Ke hadapan) | 103.09 |
| Harga / Jualan (P/S) | 1.45 |
| Harga / Buku (P/B) | 1.44 |
| Julat 52 Minggu |
| Margin Keuntungan | -21.98% |
| Margin Operasi (TTM) | -81.99% |
| EPS Cair (TTM) | -0.760 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.30% |
| Nisbah Semasa (MRQ) | 3.92 |
| Aliran Tunai Operasi (OCF TTM) | -56.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -41.71 M |
| Pulangan Atas Aset (ROA TTM) | -7.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vanda Pharmaceuticals Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.67 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.16% |
| % Dimiliki oleh Institusi | 78.96% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aqr Capital Management Llc | 30 Jun 2026 | 3,497,695 |
| Renaissance Technologies Llc | 30 Jun 2026 | 3,441,361 |
| Aigh Capital Management Llc | 30 Jun 2026 | 2,044,169 |
| Acadian Asset Management Llc | 30 Jun 2026 | 1,918,063 |
| Marshall Wace, Llp | 30 Jun 2026 | 1,225,996 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,213,326 |
| Krensavage Asset Management, Llc | 30 Jun 2026 | 1,180,388 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |